Schedule 13G ownership disclosure

NEWCELX LTD

Common Shares, par value CHF 0.05 · CUSIP: H5835A109

Event date: 2025-10-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • BIOTECHNOLOGY VALUE FUND L P

    Shares: 15,196.00 · Class: 0.3%

  • BVF I GP LLC

    Shares: 15,196.00 · Class: 0.3%

  • BIOTECHNOLOGY VALUE FUND II LP

    Shares: 11,746.00 · Class: 0.3%

  • BVF II GP LLC

    Shares: 11,746.00 · Class: 0.3%

  • Biotechnology Value Trading Fund OS LP

    Shares: 1,334.00 · Class: 0.03%

  • BVF Partners OS Ltd.

    Shares: 1,334.00 · Class: 0.03%

  • BVF GP HOLDINGS LLC

    Shares: 26,942.00 · Class: 0.6%

  • BVF PARTNERS L P/IL

    Shares: 28,732.00 · Class: 0.6%

  • BVF INC/IL

    Shares: 28,732.00 · Class: 0.6%

  • LAMPERT MARK N

    Shares: 28,732.00 · Class: 0.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000921895-25-002895
Form type
SCHEDULE 13G/A
Filer
BIOTECHNOLOGY VALUE FUND L P
CIK
CIK 918923
Filed
Nov 04, 2025
Reporting period
Oct 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub